ARTICLE OPEN

Neural responses to reward anticipation and feedback in adult and adolescent cannabis users and controls

Martine Skumlien1,2,5, Claire Mokrysz2, Tom P. Freeman2,3, Matthew B. Wall2,4,5, Michael Bloomfield6, Rachel Lee2,3, Anna Borissova2, Kat Petrilli2,3, James Carson2, Tiernan Coughlan2, Shelan Ofori2, Christelle Langley1,7, H. Valerie Curran2 and Will Lawn2,8

© The Author(s) 2022

Neuropsychopharmacology (2022) 47:1976–1983; https://doi.org/10.1038/s41386-022-01316-2

INTRODUCTION

Cannabis is the third most commonly used controlled substance worldwide, after alcohol and nicotine [1]. User rates are disproportionately high among adolescents and young adults [1], with annual prevalence rates estimated at 19.3% among 15-year olds in England [2], and 28.0% of 15–16-year olds in the United States [3]. As cannabis regulation is currently changing in many countries, it is becoming increasingly important to understand if and how long-term cannabis use impacts the brain and cognition, so that new policies can be designed to minimise harm and maximise benefit.

Adolescents may respond differently to cannabis exposure compared to adults. Adolescence is an important period of neurodevelopment, during which neural connections are selectively pruned and strengthened in an experience-driven manner [4, 5]. The endocannabinoid system, the primary neurobiological target of cannabis, is thought to play a central role in this development, and is itself an important target of neuromaturation during adolescence [6]. Therefore, many researchers have suggested that adolescence is a sensitive period for the potentially adverse effects of cannabis and other drugs [7–9]. Brain maturation during adolescence coincides temporally with key milestones in cognitive development [4, 10]. Anatomical differences between adult and adolescent samples are pronounced in frontal and striatal regions, which are important to reward and motivation [11]. Studies comparing neural reward processing in adults and adolescents suggest that while adolescents recruit a fronto-striatal network largely overlapping with that of adults [12], they may also show hyperactivity in limbic and striatal reward systems [13–15]. There are no studies to date comparing reward processing between adult and adolescent cannabis users.

Neural responses to reward anticipation and feedback in adult and adolescent cannabis users and controls

Chronic use of drugs may alter the brain’s reward system, though the extant literature concerning long-term cannabis use and neural correlates of reward processing has shown mixed results. Adolescents may be more vulnerable to the adverse effects of cannabis than adults; however, this has not been investigated for reward processing. As part of the ‘CannTeen’ study, in the largest functional magnetic resonance imaging study of reward processing and cannabis use to date, we investigated reward anticipation and feedback in 125 adult (26–29 years) and adolescent (16–17 years) cannabis users (1–7 days/week cannabis use) and gender- and age-matched controls, using the Monetary Incentive Delay task. Blood-oxygen-level-dependent responses were examined using region of interest (ROI) analyses in the bilateral ventral striatum for reward anticipation and right ventral striatum and left ventromedial prefrontal cortex for feedback, and exploratory whole-brain analyses. Results showed no User-Group or User-Group × Age-Group effects during reward anticipation or feedback in pre-defined ROIs. These null findings were supported by post hoc Bayesian analyses. However, in the whole-brain analysis, cannabis users had greater feedback activity in the prefrontal and inferior parietal cortex compared to controls. In conclusion, cannabis users and controls had similar neural responses during reward anticipation and in hypothesised reward-related regions during reward feedback. The whole-brain analysis revealed tentative evidence of greater fronto-parietal activity in cannabis users during feedback. Adolescents showed no increased vulnerability compared with adults. Overall, reward anticipation and feedback processing appear spared in adolescent and adult cannabis users, but future longitudinal studies are needed to corroborate this.

Neuropsychopharmacology (2022) 47:1976–1983; https://doi.org/10.1038/s41386-022-01316-2

1Department of Psychiatry, University of Cambridge, Cambridge, UK. 2Clinical Psychopharmacology Unit, Clinical, Educational and Health Psychology Department, University College London, London, UK. 3Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK. 4Invicro, London, UK. 5Faculty of Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK. 6Division of Psychiatry, University College London, London, UK. 7Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK. 8National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK. *email: ms2610@cam.ac.uk

Received: 24 September 2021 Revised: 15 March 2022 Accepted: 18 March 2022

Published online: 6 April 2022

SPRINGER NATURE
previous research has linked long-term recreational drug use and
dependence with blunted ventral striatal activity during reward
anticipation [19, 20]. Striatal hypoactivity has not typically been
found in cross-sectional functional magnetic resonance imaging
(fMRI) studies of cannabis users, either among adults [21–24], or
adolescents [25, 26]. However, in a longitudinal study of 108
young adults by Martz et al. [27], greater cannabis use predicted
attenuated nucleus accumbens (NAc) responses during reward
anticipation, while controlling for other substance use and family
history of substance use disorder. Thus, cannabis use in young
adulthood may be prospectively associated with blunted activity
in the NAc/ventral striatum during reward anticipation.
Conversely, previous research has not revealed differences between
cannabis users and controls in ventral striatal activity during
reward feedback [28]. Some studies have shown an association
between cannabis use and increased prefrontal and dorsal striatal
activity during feedback [21, 29, 30], though this has not been
consistently found [28].

The mixed results of previous studies raise several questions.
Firstly, with the exception of Martz et al., previous studies have
typically included small samples of 15–20 cannabis users. While
these are common sample sizes in fMRI research, replication with
larger samples is needed to determine whether differences in
findings are due to unmeasured confounders, lack of power, or
statistical variability around a null effect. Secondly, there have
been no reward processing studies comparing adult and
adolescent cannabis users directly along with age-matched
control groups. Therefore, previous research gives little indication
of whether adolescent cannabis users are more likely to show
changes in neural reward processing compared to adult cannabis
users, as might be expected based on the hypothesised adolescent
vulnerability to harmful effects of cannabis.

In the present study, we investigated reward anticipation and
reward feedback in 125 adolescent and adult cannabis users and
controls during fMRI. We proposed the following, pre-registered
[31] hypotheses:

1. Cannabis users will show lower activity in the bilateral
ventral striatum during anticipation of reward, compared to
controls.
2. There will be a significant interaction between User-Group
and Age-Group on ventral striatal activity during reward
anticipation, whereby adolescent cannabis users will show
greater attenuation than adult users.

We also conducted a whole-brain analysis to determine differences
in other regions. Previous studies have not shown a clear pattern of
differences between cannabis users and controls during reward
feedback; thus, we did not specify explicit hypotheses of group
differences for this phase. The current study is, to our knowledge, the largest fMRI study of reward processing in cannabis users to date, and the first to compare adult and adolescent cannabis users together with age-matched controls.

METHODS

Participants

The current study presents cross-sectional, baseline data from the
longitudinal arm of the CannTeen study [32]. Participants were 35
adolescent cannabis users, 35 adult cannabis users, 35 adolescent controls,
and 35 adult controls, recruited from the greater London area via school
assemblies, posters and flyers, and social media advertisements. Cannabis
users used cannabis at least once per week, on average, over the past
3 months. Adult users were excluded if they had used cannabis frequently
before the age of 18, with the objective of isolating the impact of adolescent
cannabis use. Controls had ≤10 occasions of cannabis use in their lifetime,
and no use in the month prior to the baseline behavioural
assessment. Adolescents were 16–17 years of age, and adults were 26–29
years of age. Key exclusion criteria were daily use of psychotropic
medication, past-month treatment for any mental health condition,
and having used any one illicit drug on more than 6 days over the past
3 months. Full inclusion and exclusion criteria are reported in Supplemen-
tary Table S1. All participants provided written and informed consent
to participate. The study was conducted in line with the Declaration of
Helsinki, and was approved by the University College London (UCL) ethics
committee (project ID 5929/003).

Materials

Monetary Incentive Delay task. Reward processing was assessed with the
Monetary Incentive Delay (MID) task which includes a reward anticipation
phase and a reward outcome/feedback phase [33]. At the start of each trial
a cue appeared, which signalled whether the participant could win money
on that trial (win trials: orange square) or not (neutral trials: blue square).
After the cue followed an anticipation phase, after which a target (white
circle) appeared, which the participants had to respond to as quickly as
possible in order to win. Participants could win 50 pence on win trials, and
there were no loss trials. Full details are presented in the Supplementary
materials. The MID is the most commonly used task for assessing neural
reward processing in humans [16, 34], and among cannabis users [28].

Covariates. Covariates in behavioural and ROI analyses were depression,
risk-taking, maternal education, and alcohol, tobacco, and other illicit drug
use. These were chosen a priori due to their putative interaction with
cannabis use, and reward processing [20, 35–37]. Details are presented in
the Supplementary materials.

Data acquisition

A complete account of data collection procedures is presented in the full
study protocol [32]. Participants completed an instant saliva drugs test and
a breathalyser, and self-reported abstinence, to confirm recent use of
alcohol or cannabis (≥12 h cut-off) or illicit drugs (≥48 h cut-off) at the start
of all study sessions. Drug use was assessed with the timeline followback
[38]. Questionnaire, demographic, and drug use information were
collected during a baseline behavioural session at the UCL Clinical
Psychopharmacology Unit.

The MID session was typically completed within 2 weeks and always
consisted of within 2 months of the baseline behavioural session and took
place at the Invicro MRI research facility, Hammersmith, London. MRI data
were collected with a 3.0T Siemens Magnetom Verio. T2* images were
acquired using a multiband gradient echo Echo-Planar Imaging sequence
[39]. T1-weighted structural images were acquired using a Magnetization
Prepared Rapid Gradient Echo sequence [40]. Full MRI acquisition
parameters are in the Supplementary materials.

Analysis

Analyses and hypotheses were pre-registered to the Open Science
Framework [31]. Behavioural and ROI analyses were performed in R 3.6.2
[41], using the rstatix package [42].

Behavioural analyses. Behavioural outcomes on the MID task were
success rates (% hit targets) and mean reaction times (RTs) for win and
neutral trials. The data were first inspected to ensure that the assumptions
of parametric statistics were met. Hit rate and RT were dependent variables
in separate fully factorial 2 × 2 × 2 mixed measures analyses of
covariance (ANCOVAs), with between-group factors User-Group (control vs. user)
and Age-Group (adult vs. adolescent), and within-group factor Trial-Type (win
er vs. neutral). Covariates were included as specified in the ‘Covariates’
section.

Pre-processing and first-level analyses. Pre-processing and first-
and second-level fMRI analyses were performed in FSL [43], with the fMRI
Expert Analysis Tool [44, 45]. Structural high-resolution images were pre-
processed using the fslnan script provided with FSL. Functional images
were realigned with MCFLIRT (motion correction FMRIb linear image
registration tool) [46], and normalised to MNI-152 (Montreal Neurological
Institute) space with FMRIB’s nonlinear registration tool, using a 10
mm warp resolution and 12 degrees of freedom. Spatial smoothing was
carried out using a 6 mm full-width at half-maximum Gaussian kernel. Raw
functional image series, movement estimates, and registration were
inspected for each participant.

There were six explanatory variables (EVs): anticipation of win outcomes
(Anticipate-win; EV1), anticipation of neutral outcomes (Anticipate-neutral;
EV2), feedback on successful win trials (Feedback-win-hit; EV3), feedback on unsuccessful win trials (Feedback-win-miss; EV4), feedback on successful neutral trials (Feedback-neutral-hit; EV5), and feedback on unsuccessful neutral trials (Feedback-neutral-miss; EV6). These were implemented in a general linear model, by convolving their respective onsets with a gamma function model of the hemodynamic response. Motion parameters were met. Covariates were included as regressors-of-no-interest. The FILM pre-whitening procedure was used to account for temporal autocorrelation, and a high-pass filter (100 s cut-off) was used to remove low-frequency noise. Reward anticipation was examined with the Anticipate-neutral > Anticipate-neutral contrast [1 -1 0 0 0 0], and reward feedback with the Feedback-win-hit > Feedback-win-miss contrast [0 0 1 -1 0 0].

Second-level analyses. Second-level analyses were performed with FMRIBs local analysis of mixed effects. Mean blood-oxygen-level-dependent responses across groups were first examined in a whole-brain one-sample t-test for the reward anticipation and reward feedback contrasts. We then investigated the main effects of User-Group and Age-Group, and the User-Group × Age-Group interaction with whole-brain F-tests for each contrast. Cluster-level statistics were used, with a cluster-defining threshold of $Z = 3.1 (p = 0.001)$ and a multiple test corrected cluster-extent threshold of $a = 0.05$.

ROI analyses were performed in the bilateral ventral striatum for reward anticipation, and the right ventral striatum and left vmPFC for reward feedback. ROIs were selected based on a meta-analysis by Oldham et al. [16], and defined by constructing 6 mm radius spheres around the coordinates with peak activation likelihood estimates for each contrast (Supplementary Fig. S2). Unstandardised $b$-values were extracted from the lower-level contrasts, and served as the dependent variable in separate fully factorial $2 \times 2$ ANCOVAs, with factors User-Group and Age-Group. All data were inspected to ensure that the assumptions of parametric statistics were met. Covariates were included as specified in the ‘Covariates’ section. Additional one-sample t-tests were performed for all ROIs to assess overall activation across participants, and exploratory bivariate correlations were computed between ROIs and additional cannabis use variables. Finally, for continuous data mean (SD) and range are shown. For categorical data, n (%) is shown. One alcohol unit equals 10 ml or 8 g of pure alcohol. Eleven participants had not used alcohol in the past three months. Group differences were investigated with 2 × 2 analyses of variance, independent-samples t-tests, or $\chi^2$ tests of independence. Age and hours since last use were assessed at the baseline imaging session. All other variables were assessed at the baseline behavioural session.

| Table 1. Sample characteristics. |
|----------------------------------|
| Demographics and covariates      |
| Gender                           |
| Female                          | 16 (50.0%) | 15 (48.4%) | 16 (51.6%) | ns         |
| Male                            | 16 (50.0%) | 17 (54.8%) | 15 (48.4%) | ns         |
| Age in years                    | 17.22 (0.52), 16.31–17.98 | 27.81 (1.49), 26.27–30.02 | 17.15 (0.45), 16.27–18.04 | 27.34 (0.86), 26.10–29.56 | Adults > Adolescents*** |
| Ethnicity                       | White      | 23 (71.9%) | 24 (77.4%) | 19 (61.3%) | 22 (71.0%) |
|                                | Mixed      | 6 (18.8%)  | 2 (6.5%)   | 5 (16.1%)  | 0 (0.0%)   |
|                                | Asian      | 0 (0.0%)   | 2 (6.5%)   | 4 (12.9%)  | 6 (19.4%)  |
|                                | Black      | 2 (6.3%)   | 2 (6.5%)   | 2 (6.5%)   | 2 (6.5%)   |
|                                | Other      | 1 (3.1%)   | 1 (3.2%)   | 0 (0.0%)   | 1 (3.2%)   |
|                                | Prefer to say | 0 (0.0%)  | 0 (0.0%)   | 1 (3.2%)   | 0 (0.0%)   |
| Maternal education             |
| Below undergraduate degree      | 14 (45.2%) | 13 (41.9%) | 12 (38.7%) | 19 (63.3%) | ns         |
| Undergraduate degree or above   | 17 (54.8%) | 18 (58.1%) | 19 (61.3%) | 11 (36.7%)* |
| BDI                             | 10.09 (3.88), 1–31 | 7.71 (10.42), 0–46 | 9.13 (5.66), 0–26 | 7.55 (8.90), 0–39 | ns         |
| RT-18                           | 11.50 (2.45), 3–18 | 7.90 (4.04), 3–15 | 8.52 (4.08), 0–17 | 7.74 (4.54), 0–16 | Users > Controls* Adolescents > Adults** |
| Alcohol use, days/week          | 0.87 (0.79), 0–0.25 | 1.49 (1.31), 0–5.25 | 0.71 (0.81), 0–3.67 | 1.49 (1.27), 0–5.25 | Adolescents*** |
| Typical number of units on a day of drinking | 7.85 (5.82), 0–20 | 5.97 (4.78), 0–21 | 3.63 (4.18), 0–16 | 3.83 (2.96), 0–15 | Users > Controls*** |
| Cigarette/roll-up use, days/week | 2.31 (2.82), 0–7 | 1.45 (2.66), 0–7 | 0.52 (1.56), 0–6.5 | 0.55 (1.76), 0–7 | Users > Controls*** |
| Cigarettes per day if daily smoker | 4.80 (3.27), 1–10, n = 5 | 5.70 (3.11), 2–10, n = 5 | 1 (NA), n = 1 | 13.75 (8.34), 7.5–20, n = 2 | ns         |
| Other illicit drug use, monthly use |
| Yes                             | 18 (56.25%) | 7 (22.6%)  | 1 (3.2%)   | 0 (0.0%)   | Adolescents > Adults* |
| No                              | 14 (43.75%) | 24 (77.4%) | 30 (96.8%) | 31 (100.0%) | ns         |
| Cannabis use                    |
| Ever use (controls)             | 27 (87.1%) | 30 (96.8%) | ns         |
| Number of lifetime uses (controls) | 3.61 (3.04), 0–10 | 4.84 (3.26), 0–10 | ns         |
| Days/week of use (users)        | 3.23 (2.16), 0.83–6.92 | 3.82 (2.14), 0.75–6.92 | ns         |
| Grams used on a day of use (users) | 0.90 (0.76), 0.15–4 | 0.77 (0.88), 0.03–3.5* | ns         |
| Hours since last use (users)    | 44.39 (32.72), 12.50–136.0 | 41.58 (45.13), 12.08–185.0 | ns         |
| Age of first-ever use (users)   | 14.65 (1.10), 12.0–16.5 | 17.64 (3.13), 13.0–24.08 | Adolescents*** |
| Age of first weekly use (users) | 15.75 (1.08), 13.25–17.67 | 22.06 (2.88), 17.0–27.67 | Adolescents*** |
| CUDIT (users)                   | 14.56 (5.58), 5–26 | 11.87 (5.93), 3–26 | ns         |
| DSM-5 severe CUD (users)        | 13 (40.6%)  | 6 (19.4%)  | ns         |
Table 2. Whole-brain analysis results for the Monetary Incentive Delay task.

| X       | Y    | Z   | K    | Z   |
|---------|------|-----|------|-----|
| Reward anticipation across the full sample (anticipate-reward > anticipate-neutral) | 4 | 16 | 40 | 114,852 | 11.1 |
| Paracingulate gyrus R | 12 | 6 | 42 | 10.7 |
| Local maxima | 2 | 4 | 40 | 10.5 |
| Anterior cingulate gyrus L | 34 | 22 | −4 | 10.7 |
| Anterior cingulate gyrus R | 2 | 4 | 40 | 10.5 |
| Reward feedback across the full sample (feedback-win-hit > feedback-win-miss) | 44 | −54 | 34 | 471 | 4.25 |
| Ocipital pole L | 24 | 40 | 54 | 311 | 5.51 |
| Lateral occipital cortex L | 34 | 90 | 2 | 9.93 |
| Nucleus accumbens R | 12 | 4 | −10 | 9.3 |
| Nucleus accumbens L | 10 | −6 | −10 | 9.29 |
| Frontal pole R | 24 | 40 | 54 | 311 | 5.51 |
| Main effect of User-Group for reward feedback (feedback-win-hit > feedback-win-miss), Users > Controls | 58 | −42 | 24 | 3.86 |
| Supramarginal gyrus (posterior) R | −6 | −52 | 38 | 4.28 |
| Angular gyrus L | 26 | 66 | 14 | 275 | 4.34 |
| Lateral occipital cortex L | 34 | 90 | 2 | 9.93 |
| Frontal pole R | 34 | 22 | 10 | 10.7 |
| Superior frontal gyrus R | 0 | 12 | 66 | 192 | 4.13 |
| Local maxima | 12 | 12 | 74 | 3.42 |

X, Y, and Z are coordinates in MNI-space. K refers to the number of voxels in the cluster. Peak Z values are reported for each cluster, and local maxima within clusters, where relevant.

Bayesian analyses were performed with values from independent-samples t-tests of users compared to controls and adult users compared to adolescent users, using the BayesianFactor package in R [47]. A scaled-information prior of $r = 0.707$ was used, and Jeffrey's-Zellner-Siow Bayes factors (BF) above 3 were interpreted as meaningful [48].

RESULTS

Sample characteristics

Six participants were excluded due to abnormal behavioural data, as specified in the analysis protocol [31], indicating they had not performed the task correctly. An additional nine participants were excluded due to large head movement or other MRI artefacts. Thus, $n = 125$ participants were carried forward for analysis (see Table 1). Two participants (one adolescent user, one adult control) did not have data on maternal education, and were excluded from the behavioural and ROI analyses. They were not excluded from the whole-brain analyses, as these did not include this covariate.

Behavioural analyses

Descriptive statistics and full results of the behavioural analyses are presented in Supplementary Tables S3 and S4. The main effect for Trial-Type was significant for both success rate ($F_{1,113} = 17.43, p < 0.001, \eta^2_p = 0.13$) and mean RT ($F_{1,113} = 4.74, p = 0.03, \eta^2_p = 0.04$). Participants had higher success rates and shorter RTs for win trials compared to neutral trials (mean difference 18.87% and 6 ms). There were no significant main or interaction effects of User-Group or Age-Group.

Whole-brain analyses

Significant clusters and local maxima are presented in Table 2. Regions were labelled using the Harvard–Oxford cortical and subcortical structural atlases [49–51]. The one-sample t-test revealed a large cluster of activation during reward anticipation, with peaks in the anterior cingulate cortex and anterior insula (Supplementary Fig. S5). There were no significant main or interaction effects of User-Group or Age-Group in any region during reward anticipation. Peak activation across all participants during reward feedback was found in the occipital cortex, NAc, and frontal pole (Supplementary Fig. S5). There was a significant effect of User-Group in the bilateral inferior parietal cortex, and right frontal pole, with greater activation in users than controls. There was also a significant effect of Age-Group in the bilateral superior frontal gyrus, with greater activation in adults than adolescents. Figure 1 shows regions with significant User-Group or Age-Group differences in reward feedback activity.

ROI analyses

Full results of the ROI analyses are presented in Supplementary Table S6 and Supplementary Fig. S7. Given that the covariates were not specified in our pre-registered analysis protocol, results without covariates are presented in Supplementary Table S8. Effects of interest were similar in both sets of models.

A one-sample t-test confirmed activation in the bilateral ventral striatum during reward anticipation ($t_{1,113} = 5.89, p < 0.001, d = 0.53$). There were no significant effects of User-Group ($F_{1,113} = 0.02, p = 0.90, \eta^2_p < 0.001$), Age-Group ($F_{1,113} = 1.15, p = 0.29, \eta^2_p = 0.01$), or the User-Group × Age-Group interaction ($F_{1,113} = 0.01, p = 0.91, \eta^2_p < 0.001$). Bayesian analyses suggested that the null hypothesis of no difference in ventral striatum activity was four times more likely than the alternative when comparing users and controls (BF = 4.54), and three times more likely when comparing adult and adolescent users (BF = 3.21), assuming equal prior probabilities. There was significant activity in the right ventral striatum ($F_{1,113} = 3.21, p < 0.001, d = 0.84$) and the left vmPFC ($F_{1,113} = 8.11, p < 0.001, d = 0.73$) during reward feedback. The main effect of User-Group and the User-Group × Age-Group interaction effect were not significant for right ventral striatum (main effect: $F_{1,113} = 0.20, p = 0.66, \eta^2_p = 0.002$; interaction: $F_{1,113} = 0.84, p = 0.36, \eta^2_p = 0.007$) or left vmPFC (main effect: $F_{1,113} = 0.03, p = 0.96, \eta^2_p < 0.001$; interaction: $F_{1,113} = 0.22, p = 0.64, \eta^2_p = 0.002$). The effect of Age-Group was significant for left vmPFC ($F_{1,113} = 4.60, p = 0.03,$
\[ \eta_p^2 = 0.039 \), but not right ventral striatum (\( F_{1,113} = 0.67, p = 0.41 \), \( \eta_p^2 = 0.006 \). This effect was driven by adults activating more than adolescents. Bayesian analyses supported the null hypothesis of no difference in right ventral striatal feedback activity between users and controls (BF = 5.08) and adult and adolescent users (BF = 3.27). Anecdotal evidence in favour of the null hypothesis was found for left vmPFC feedback activity comparing users and controls (BF = 2.95) \[48\].

Bivariate correlations between ROIs and additional cannabis use variables are presented in Supplementary Table S9. There was a significant negative correlation between symptoms of cannabis use disorder and feedback activity in the right ventral striatum (\( r = -0.320, p = 0.01 \). This correlation survived correction for multiple comparisons at \( q = 0.1 \), but not at \( q = 0.05 \). All other correlations were non-significant.

**DISCUSSION**

In the present study, we found that adult and adolescent cannabis users and controls did not differ in neural activity during reward anticipation, or during feedback in pre-defined ROIs. There was no evidence in favour of adolescent vulnerability. Null findings in the ventral striatum for cannabis users compared to controls, and for adult users compared to adolescent users, were supported by Bayesian analyses. However, cannabis users showed hyperactivity in the inferior parietal cortex and right frontopolar cortex during reward feedback, in the whole-brain analysis.

**Reward anticipation and cannabis use**

The lack of significant differences in ventral striatum reward anticipation activity was contrary to our hypotheses, though is largely consistent with previous cross-sectional studies of reward
anticipation in cannabis users [28]. Even in the longitudinal study by Martz et al. [27], which found a longitudinal effect of cannabis, there was no cross-sectional association between reward anticipation at baseline and previous cannabis use. One previous study did find attenuated anticipation activity in the NAC in cannabis users compared to controls [30], but this study included only 27 users and controls, and did not control for other drug use or mental health variables.

The present sample had a lower frequency of cannabis use compared to some previous fMRI studies of reward processing in cannabis users [24, 29], though similar to others [23, 52, 53]. It is possible that differences would have emerged with more frequent or problematic use. However, bivariate correlations did not reveal a significant association between ventral striatum reward anticipation activity and cannabis use frequency, quantity, length of abstinence, age of onset, symptoms of dependence, or cannabis use disorder (Supplementary Table S9). Thus, the current results, including the Bayesian analyses, and in combination with previous evidence, suggest that there is no association between cannabis use and altered neural responses to reward anticipation cross-sectionally.

It is possible that previous differences between cannabis users and controls were confounded by concurrent use of tobacco/nicotine [20]. Co-use of cannabis and cigarettes is common, and many users consume cannabis together with tobacco in joints [36, 54]. Previous studies have found an association with blunted striatal activity during reward anticipation more consistently for nicotine than for cannabis [19, 26]. The effects of acute cannabis on striatal reward processing have also been shown to differ depending on comorbid nicotine dependence [55]. In addition, in the current study, there was a significant effect of the cigarette covariate (Supplementary Table S6), in the direction of lower ventral striatum anticipation activity with a higher frequency of cigarette use. This was the only significant effect for the reward anticipation models, and suggests that cigarette use may have an effect independent of cannabis use. Future studies should attempt to demarcate the relative contributions of cannabis and tobacco/nicotine on striatal reward anticipation.

Reward feedback and cannabis use

Previous studies have not found a consistent association between cannabis use and neural responses to reward feedback [28]. In the current study, there were no differences in ROIs pre-defined based on a large meta-analysis [16]. However, a whole-brain analysis revealed greater activity in the right frontopolar cortex and bilateral inferior parietal cortex in cannabis users. Interestingly, this difference was driven by opposite patterns of activity for successful win-trial feedback compared to unsuccessful win-trial feedback in cannabis users and controls. While users activated the right frontopolar and bilateral inferior parietal cortex after a successful win, controls deactivated the same areas. This pattern has not emerged previously, though two earlier studies did find hyperactivity in different regions of the prefrontal cortex in cannabis users during feedback [29, 30], somewhat consistent with the present findings.

The present study found no differences between cannabis users and controls in regions that are commonly activated during reward feedback [16]. The current results may thus not reflect a reward-specific effect, but rather a general trend towards neural hyperactivation in cannabis users. Several previous studies have found increased fronto-parietal activation in cannabis users during cognitive tasks [56], especially in adolescent users [57]. This has been proposed to reflect a neural compensatory mechanism in cannabis users, such that greater activation helps to achieve normal levels of behavioural performance [58, 59]. Accordingly, hyperactivation in frontopolar and inferior parietal cortex in cannabis users may have occurred in order to achieve similar performance to controls on the MID task in the current study.

However, this interpretation is speculative. The present differences in fronto-parietal activity may also reflect pre-existing vulnerabilities in cannabis users relative to controls, such as attentional disparities [60, 61]. Longitudinal studies are needed to establish the potential mechanisms underlying differences in neural reward feedback activity between cannabis users and controls.

No adolescent vulnerability

Most crucially, the present results did not support our hypotheses of an interaction between User-Group and Age-Group on reward anticipation. There was also no significant interaction for feedback. Results were supported by Bayesian analyses. Adolescent and adult users were well matched in frequency and quantity of use, and group differences were generally in the direction of higher levels among adolescent users on variables that would likely confer greater risk (i.e., abuse and dependence, early onset of use, other drug use). Thus, our results suggest that adolescent cannabis users are not at greater risk of altered neural reward processing compared to adult users. This could be because cannabis does not disrupt the reward system non-acutely, regardless of age. Alternatively, it may be that the striatal reward system has matured by age 16–17 and is therefore not sensitive to disruption at this age [15, 62]. Importantly, there is evidence that adolescent users are at greater risk of other cannabis-related adverse outcomes, such as dependence [63–65]. Moreover, adolescent cannabis users may be more vulnerable to syndromes of disrupted reward processing, such as anhedonia [66]. Therefore, psychological and behavioural differences may still exist in the absence of significant differences in neural activity in pre-defined brain areas, using the present task and methods. A brief discussion of the main age-group effect is provided in the Supplementary materials.

Clinical and policy implications

Although the present neuroimaging study is not clinical in nature, it has some relevance to treatment strategy. Our findings are inconsistent with models suggesting that cannabis dependence is subserved by blunted neural responsiveness to non-cannabis rewards [67, 68]. Thus, we should not assume anticipatory neural processing of natural rewards is impaired in chronic cannabis users and require treatments to redress a purported deficiency. This is not to say that treatment should ignore natural rewards, as contingency management and behavioural activation may have efficacy in the treatment of cannabis use disorder [69, 70]. Future research should integrate fMRI into clinical trials or observational treatment studies to examine the complex role of neural reward processing in illness and recovery. Our findings are also relevant to the development of evidence-based harm reduction strategies, use of medical cannabis, and drug education, with knowledge of the long-term effects on brain and cognition imperative. Finally, as more countries regulate recreational and medical cannabis, minimum age-of-purchase limits will be implemented. Our results suggest 16–17-year olds are not at greater risk of cannabis-related disruption of neural reward processing. Nevertheless, adolescent vulnerability to other cannabis-related harms should be investigated, and influence policy development.

Strengths and limitations

The most notable limitation of the current study is the cross-sectional design. This means that we cannot exclude the possibility that pre-existing group differences obscured an effect of cannabis use on reward processing. However, key confounders including depression, risk-taking, maternal education, and alcohol, cigarette, and illicit drug use were controlled statistically in ROI and behavioural analyses, and groups were carefully matched on key variables. Another limitation concerns our use of monetary reward exclusively. It may be that the reward system shows greater changes in response to other rewards, such as cannabis

M. Skumlien et al.
cues, which could also be linked with craving and withdrawal symptoms [71]. Strengths of the current study include the relatively large sample size, pre-registration of analyses, rigorous assessment of cannabis and other drug use with the timeline followback, biological verification of recent abstinence, good control of important confounders, matching of adolescent and adult users for the level of cannabis use, and the novel comparison of adult and adolescent user-groups with age-matched controls. Thus, the current study was well-powered to detect a difference between cannabis users and controls, compared to previous research.

CONCLUSION
In the present study, cannabis users were found to overactivate fronto-parietal networks relative to controls during reward feedback. Future longitudinal studies are needed to corroborate this. Future studies should include adolescent users in particular, and continue to adjust for important confounders such as tobacco/nicotine use. Overall, our results suggest that reward anticipation and feedback processing in key reward regions are unaffected by cannabis use at a moderate frequency of 3 to 4 days per week, and that adolescents are not at increased vulnerability to cannabis-related differences in neural reward processing.

REFERENCES
1. United Nations Office on Drugs and Crime. World Drug Report 2020. 2020.
2. NHS Digital Lifestyles Team. Smoking, drinking and drug use among young people in England 2018 [NS]. 2018.
3. National Institute on Drug Abuse. Monitoring the future study: trends in prevalence of various drugs. 2020.
4. Giedd JN. Structural magnetic resonance imaging of the adolescent brain. Ann N Y Acad Sci. 2004;1021:77–85.
5. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci. 1999;2:861–3.
6. Viveros M, Llorente R, Suarez J, Llorente-Berzal A, Lopez-Gallardo M, Rodriguez de Fonseca F. The endocannabinoid system in critical neurodevelopmental periods: sex differences and neuropsychiatric implications. J Psychopharmacol. 2012;26:164–76.
7. Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoïd system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol. 2010;92:230–8.
8. Lubman DI, Cheeetham A, Yuel M. Cannabis and adolescent brain development. Pharmac Ther. 2015;148:1–16.
9. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol. 2008;13:253–63.
10. Gogaty N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis AC, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci USA. 2004;101:8174–9.
11. Sowell ER, Thompson PM, Holmes CJ, Jerina LG, Toga AW. In vivo evidence for post-adolescent brain maturation in frontal and striatal regions. Nat Neurosci. 1999;2:859–61.
12. Cao Z, Bennett M, Orr C, Icke I, Banaschewski T, Barker GJ, et al. Mapping adolescent reward anticipation, receipt, and prediction error during the Monetary Incentive Delay task. Hum Brain Mapp. 2019;40:262–83.
13. Silverman MH, Jedd K, Luciana M. Neural networks involved in adolescent reward processing: an activation likelihood estimation meta-analysis of functional neuroimaging studies. Neuroimage. 2015;122:427–39.
14. Galvan A. Adolescent development of the reward system. Front Hum Neurosci. 2010;4:6.
15. Richards JM, Plate RC, Ernst M. A systematic review of MRFI reward paradigms used in studies of adolescents vs. adults: the impact of task design and implications for understanding neurodevelopment. Neurosci Biobehav Rev. 2013;37:975–91.
16. Oldham SM, Murawski C, Fornito A, Yousef G, Yuel M, Lorenzetti V. The anticipation and outcome phases of reward and loss processing: a neuroimaging meta-analysis of the Monetary Incentive Delay task. Hum Brain Mapp. 2018;39:3398–418.
17. Knutson B, Greer SM. Anticipatory affect: neural correlates and consequences for choice. Philos Trans R Soc Lond B Biol Sci. 2008;363:3771–86.
18. Robbins TW, Everitt BJ. Limbic-striatal memory systems and drug addiction. Neurobiol Learn Mem. 2002;78:625–36.
19. Luitjen M, Schellekens AF, Kühn S, Machiels MW, Sessoucose G. Disruption of reward processing in addiction: an image-based meta-analysis of functional magnetic resonance imaging studies. JAMA Psychiatry. 2017;74:387–98.
20. Balodis IM, Potenza MN. Anticipatory reward processing in addicted populations: a focus on the Monetary Incentive Delay task. Biol Psychiatry. 2015;77:434–44.
21. Enzi B, Lissek S, Edel MA, Tegenthoff M, Nicolas V, Scherbaum N, et al. Alterations of monetary reward and punishment processing in chronic cannabis users: an FMRI study. PLoS One. 2015;10:e0119150.
22. Filbey FM, Dunlop J, Myers US. Neural effects of positive and negative incentives during marijuana withdrawal. PLoS One. 2013;8:e61470.
23. Yip SW, DelVito EE, Kober H, Worhunsky PD, Carroll KM, Potenza MN. Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: an exploratory study of relationships with abstinence during behavioral treatment. Drug Alcohol Depend. 2014;140:33–41.
24. Nestor L, Hester R, Garavan H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage. 2010;49:1133–43.
25. Jager G, Block RI, Luitjen M, Ramsey NF. Tentative evidence for striatal hyperactivity in adolescent cannabis-using boys: a cross-sectional multicenter fMRI study. J Psychoact Drugs. 2013;45:156–67.
26. Karoly HC, Bryan AD, Weiland BJ, Mayer A, Dodd A, Feldstein Ewing SW. Does incentive-elicited nucleus accumbens activation differ by substance of abuse? An examination with adolescents. Dev Cogn Neurosci. 2015;16:5–15.
27. Martz ME, Trucco EM, Cope LM, Hardee JE, Jester JM, Zucker RA, et al. Association of marijuana use with blunted nucleus accumbens response to reward anticipation. JAMA Psychiatry. 2016;73:838–44.
28. Skumlien M, Langley C, Lawin W, Voon V, Curnan HV, Roiser JP, et al. The acute and non-acute effects of cannabis on reward processing: a systematic review. Neurosci Biobehav Rev. 2021;130:512–28.
29. Acheson A, Ray KL, Hines CS, Li K, Davies MA, Mathias CW, et al. Functional activation and effective connectivity differences in adolescent marijuana users performing a simulated gambling task. J Addict. 2015;2015:783106.
30. van Hell HH, Vink M, Ossewaarde L, Jager G, Kahn RS, Ramsey NF. Chronic effects of cannabis use on the human reward system: an fMRI study. Eur Neuropsychopharmacol. 2010;20:153–63.
31. Skumlien M, Mokrysz C, Wall MB, Freeman TP, Langley C, Sahakian BJ, et al. Neural response to reward anticipation and feedback in adult and adolescent cannabis users. 2020. [https://osf.io/ae9c9/]. Accessed 22 Sept 2021.
32. Lawn W, Mokrysz C, Borissova A, Lees R, Petrilli K, Bloomfield MA, et al. cannteen: how does long-term cannabis use affect teenagers' and adults' cognition, mental health and brains? 2020. [https://osf.io/jg9qp/]. Accessed 22 Sept 2021.
33. Knutson B, Westdorp A, Kaiser E, Hommer D. FMRI visualization of brain activity during a Monetary Incentive Delay task. Neuroimage. 2000;12:20–7.
34. Lutz K, Widmer M. What can the Monetary Incentive Delay task tell us about the neural processing of reward and punishment? Neurosci Neuroeconomics. 2013;3:43–55.
35. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction. 2006;101:556–69.
36. Millar SR, Mongan D, O'Dwyer C, Long J, Smyth BP, Perry L, et al. Correlates of patterns of cannabis use, abuse and dependence: evidence from two national surveys in Ireland. Eur J Public Health. 2021;31:441–7.
37. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325:1195–8.
38. Robinson SM, Sobell LC, Sobell MB, Leo GJ. Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28:154–62.
39. Demetroiu L, Kowalczyk OS, Tyson G, Beljo T, Newbould RD, Wall MB. A comprehensive evaluation of increasing temporal resolution with multiband-accelerated protocols and effects on statistical outcome measures in fMRI. Neuroimage. 2018;176:404–16.
40. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–91.
41. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019.
42. Kassambara A. R: pictools: Pipe-Friendly Framework for Basic Statistical Tests. 2021.
43. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004(33(Suppl 1))3280–3289.
44. Woolrich MW, Ripley BD, Brady M, Smith SM, Temporal autocorrelation in univariate linear modeling of fMRI data. Neuroimage. 2001;14:1370–86.
45. Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM, Multilevel linear modeling for FMRI group analysis using Bayesian inference. Neuroimage. 2004;21:1732–47.
67. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, et al. Reward Skumlien M, Langley C, Lawn W, Voon V, Sahakian BJ. Apathy and anhedonia in Lecung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis Ehlers CL, Gizer IR, Vieten C, Gilder DA, Stouffer GM, Lau P, et al. Cannabis Wrege J, Schmidt A, Walter A, Smieskova R, Bendfeldt K, Radue EW, et al. Effects of cannabis use in adolescence: a review of neuropsychopharmacology and function M. Skumlien et al.

ACKNOWLEDGEMENTS

We are thankful to all participants of the CannTeen study. We are grateful to all those who contributed to the data collection for this study. We also thank Professor Joseph Devlin for his help with data analysis, and Sharineet Dhiman for all her work on the project.

AUTHOR CONTRIBUTIONS

HVC was the principal investigator for the CannTeen study. HVC, CM, TPF, WL, MB and MBW contributed to the conception and design of the study. CM, WL, MBW, MB, RL, KP, AB, JC, TC, SO and MS contributed to the data collection. MS analysed the data, with critical input from WL, MBW, CL, and BSJ. MS drafted the manuscript, with critical revision from WL, CL and BSJ. All authors contributed to the interpretation of data, and revised the manuscript. All authors are responsible for the reported research, and have approved the manuscript as submitted.

FUNDING

This study was funded by a grant from the Medical Research Council, MR/P012728/1, to HVC and TPF. MS is funded by an Aker Scholarship from the Aker Foundation. AB was funded by a fellowship from the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre. BJS receives funding from the Welllatt Foundation, Eton College, and a Wellcome Trust Collaborative Award 200811/Z/15/Z, CL is funded by a Wellcome Trust Collaborative Award 200811/Z/15/Z, and their research is conducted within the NIHR Cambridge Biomedical Research Centre (Mental Health Theme and Neurodegeneration Theme) and the NIHR Brain Injury MedTech and in vitro diagnostics Co-operative (JMIG, Cambridge). HVC is supported by grants from the UK MRC (MR/P012728/1) UK Department of Health, and by the NIHR UCLH Biomedical Research Centre.

COMPETING INTERESTS

BSJ consults for Cambridge Cognition and Greenfield BioVentures. HVC has consulted for Janssen Research and Development. MBW’s primary employer is Invico LLC, a contract research organisation that performs commercial research for the pharmaceutical and biotechnology industries. The remaining authors have no conflicts of interest to disclose.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41386-022-01316-2.

Correspondence and requests for materials should be addressed to Martine Skumlien.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

71. Filbey FM, Dunlop J, Ketcherside A, Baine J, Rhinehard T, Kuhn B, et al. fMRI study of M. Skumlien et al. 1983 of neural sensitization to hedonic stimuli in long-term, daily cannabis users. Hum Brain Mapp. 2016;37:3431–43.

66. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, et al. Reward Skumlien M, Langley C, Lawn W, Voon V, Sahakian BJ. Apathy and anhedonia in Lecung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis Ehlers CL, Gizer IR, Vieten C, Gilder DA, Stouffer GM, Lau P, et al. Cannabis Wrege J, Schmidt A, Walter A, Smieskova R, Bendfeldt K, Radue EW, et al. Effects of cannabis use in adolescence: a review of neuropsychopharmacology and function M. Skumlien et al.

ACKNOWLEDGEMENTS

We are thankful to all participants of the CannTeen study. We are grateful to all those who contributed to the data collection for this study. We also thank Professor Joseph Devlin for his help with data analysis, and Sharineet Dhiman for all her work on the project.

AUTHOR CONTRIBUTIONS

HVC was the principal investigator for the CannTeen study. HVC, CM, TPF, WL, MB and MBW contributed to the conception and design of the study. CM, WL, MBW, MB, RL, KP, AB, JC, TC, SO and MS contributed to the data collection. MS analysed the data, with critical input from WL, MBW, CL, and BSJ. MS drafted the manuscript, with critical revision from WL, CL and BSJ. All authors contributed to the interpretation of data, and revised the manuscript. All authors are responsible for the reported research, and have approved the manuscript as submitted.

FUNDING

This study was funded by a grant from the Medical Research Council, MR/P012728/1, to HVC and TPF. MS is funded by an Aker Scholarship from the Aker Foundation. AB was funded by a fellowship from the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre. BJS receives funding from the Welllatt Foundation, Eton College, and a Wellcome Trust Collaborative Award 200811/Z/15/Z, CL is funded by a Wellcome Trust Collaborative Award 200811/Z/15/Z, and their research is conducted within the NIHR Cambridge Biomedical Research Centre (Mental Health Theme and Neurodegeneration Theme) and the NIHR Brain Injury MedTech and in vitro diagnostics Co-operative (JMIG, Cambridge). HVC is supported by grants from the UK MRC (MR/P012728/1) UK Department of Health, and by the NIHR UCLH Biomedical Research Centre.

COMPETING INTERESTS

BSJ consults for Cambridge Cognition and Greenfield BioVentures. HVC has consulted for Janssen Research and Development. MBW’s primary employer is Invico LLC, a contract research organisation that performs commercial research for the pharmaceutical and biotechnology industries. The remaining authors have no conflicts of interest to disclose.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41386-022-01316-2.

Correspondence and requests for materials should be addressed to Martine Skumlien.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

71. Filbey FM, Dunlop J, Ketcherside A, Baine J, Rhinehard T, Kuhn B, et al. fMRI study of neural sensitization to hedonic stimuli in long-term, daily cannabis users. Hum Brain Mapp. 2016;37:3431–43.

66. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, et al. Reward Skumlien M, Langley C, Lawn W, Voon V, Sahakian BJ. Apathy and anhedonia in Lecung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis Ehlers CL, Gizer IR, Vieten C, Gilder DA, Stouffer GM, Lau P, et al. Cannabis Wrege J, Schmidt A, Walter A, Smieskova R, Bendfeldt K, Radue EW, et al. Effects of cannabis use in adolescence: a review of neuropsychopharmacology and function M. Skumlien et al.

ACKNOWLEDGEMENTS

We are thankful to all participants of the CannTeen study. We are grateful to all those who contributed to the data collection for this study. We also thank Professor Joseph Devlin for his help with data analysis, and Sharineet Dhiman for all her work on the project.

AUTHOR CONTRIBUTIONS

HVC was the principal investigator for the CannTeen study. HVC, CM, TPF, WL, MB and MBW contributed to the conception and design of the study. CM, WL, MBW, MB, RL, KP, AB, JC, TC, SO and MS contributed to the data collection. MS analysed the data, with critical input from WL, MBW, CL, and BSJ. MS drafted the manuscript, with critical revision from WL, CL and BSJ. All authors contributed to the interpretation of data, and revised the manuscript. All authors are responsible for the reported research, and have approved the manuscript as submitted.

FUNDING

This study was funded by a grant from the Medical Research Council, MR/P012728/1, to HVC and TPF. MS is funded by an Aker Scholarship from the Aker Foundation. AB was funded by a fellowship from the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre. BJS receives funding from the Welllatt Foundation, Eton College, and a Wellcome Trust Collaborative Award 200811/Z/15/Z, CL is funded by a Wellcome Trust Collaborative Award 200811/Z/15/Z, and their research is conducted within the NIHR Cambridge Biomedical Research Centre (Mental Health Theme and Neurodegeneration Theme) and the NIHR Brain Injury MedTech and in vitro diagnostics Co-operative (JMIG, Cambridge). HVC is supported by grants from the UK MRC (MR/P012728/1) UK Department of Health, and by the NIHR UCLH Biomedical Research Centre.

COMPETING INTERESTS

BSJ consults for Cambridge Cognition and Greenfield BioVentures. HVC has consulted for Janssen Research and Development. MBW’s primary employer is Invico LLC, a contract research organisation that performs commercial research for the pharmaceutical and biotechnology industries. The remaining authors have no conflicts of interest to disclose.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41386-022-01316-2.

Correspondence and requests for materials should be addressed to Martine Skumlien.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022

Neuropsychopharmacology (2022) 47:1976 – 1983

Springer Nature